Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
Introduction: Selective RET inhibitors are approved for the treatment of RET-dependent cancers. A comprehensive characterization of mucocutaneous adverse events (MAEs) has not been performed; therefore, we characterized MAEs associated with the selective RET inhibitor, selpercatinib. Methods: We ass...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364325000086 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087389854498816 |
|---|---|
| author | Rachel E. Reingold, MD Rose Parisi, MD, MBA Guilherme Harada, MD Andrea P. Moy, MD George Dranitsaris, PhD Jasmine H. Francis, MD Julia Canestraro, OD, FAAO Julia A. Lester, MPH Lauren A. Kaplanis, RN Dazhi Liu, PharmD, BCOP Mario E. Lacouture, MD Alexander Drilon, MD |
| author_facet | Rachel E. Reingold, MD Rose Parisi, MD, MBA Guilherme Harada, MD Andrea P. Moy, MD George Dranitsaris, PhD Jasmine H. Francis, MD Julia Canestraro, OD, FAAO Julia A. Lester, MPH Lauren A. Kaplanis, RN Dazhi Liu, PharmD, BCOP Mario E. Lacouture, MD Alexander Drilon, MD |
| author_sort | Rachel E. Reingold, MD |
| collection | DOAJ |
| description | Introduction: Selective RET inhibitors are approved for the treatment of RET-dependent cancers. A comprehensive characterization of mucocutaneous adverse events (MAEs) has not been performed; therefore, we characterized MAEs associated with the selective RET inhibitor, selpercatinib. Methods: We assessed 133 patients with RET-altered cancers treated with selpercatinib. The type, grade, cumulative incidence, and time to onset of MAEs were determined. Therapy interruptions, clinicopathologic findings, and management were described. Laboratory values were compared between patients with and without MAEs. Results: A total of 73 patients with mostly NSCLC (n = 46, 63%), medullary thyroid (n = 19, 26%), and papillary thyroid (n = 6, 8%) cancers had 126 predominantly grade 1/2 (n = 124, 98%) MAEs, with 48% reporting greater than one MAE. Xerostomia (n = 49, 37%), rash (n = 24, 18%), periorbital edema (n = 16, 12%), and xerosis (n = 12, 9%) were the most common MAEs. The yearly cumulative incidence of all-grade MAEs was 55%, with a median time to onset of 57 (interquartile range: 15–166) days after initiation. Those with MAEs had a significantly higher percentage of lymphocytes (mean = 21.8, SD = 11.3, p = 0.005) compared with those without MAEs (16.9, SD = 10.0) and elevated immunoglobulin E (mean = 275, SD = 294.5 IU/mL). There were 18 (14%) MAE-related therapy interruptions, including the following: three (2%) rechallenged with dose maintained, 10 (7%) with a 50% dose reduction, 5 (4%) with a 25% dose reduction, and no drug discontinuations. A treatment algorithm was created for the most common MAEs: xerostomia managed with saliva and lubricants; mucositis with steroid rinses; rashes with topical steroids with or without topical ammonium lactate; periorbital edema with cold or caffeine compresses; and xerosis and pruritus with emollients. Conclusions: Selective RET inhibition is associated with a unique MAE profile. Early recognition and management of MAEs may improve quality of life, minimize interruptions, and maximize therapeutic benefit. |
| format | Article |
| id | doaj-art-86fff4dcdf624235bbc62f09b66ba6e9 |
| institution | Kabale University |
| issn | 2666-3643 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj-art-86fff4dcdf624235bbc62f09b66ba6e92025-02-06T05:12:51ZengElsevierJTO Clinical and Research Reports2666-36432025-03-0163100792Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)Rachel E. Reingold, MD0Rose Parisi, MD, MBA1Guilherme Harada, MD2Andrea P. Moy, MD3George Dranitsaris, PhD4Jasmine H. Francis, MD5Julia Canestraro, OD, FAAO6Julia A. Lester, MPH7Lauren A. Kaplanis, RN8Dazhi Liu, PharmD, BCOP9Mario E. Lacouture, MD10Alexander Drilon, MD11Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Weill Cornell Medical College, New York, New YorkDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Early Drug Development Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkDermatopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New YorkDepartment of Public Health, Falk College, Syracuse University, Syracuse, New YorkOphthalmic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkOphthalmic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkOphthalmic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Early Drug Development Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Early Drug Development Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Weill Cornell Medical College, New York, New YorkThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Early Drug Development Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York; Corresponding author: Address for correspondence: Alexander Drilon, MD, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E 74th St, New York 10021, New York.Introduction: Selective RET inhibitors are approved for the treatment of RET-dependent cancers. A comprehensive characterization of mucocutaneous adverse events (MAEs) has not been performed; therefore, we characterized MAEs associated with the selective RET inhibitor, selpercatinib. Methods: We assessed 133 patients with RET-altered cancers treated with selpercatinib. The type, grade, cumulative incidence, and time to onset of MAEs were determined. Therapy interruptions, clinicopathologic findings, and management were described. Laboratory values were compared between patients with and without MAEs. Results: A total of 73 patients with mostly NSCLC (n = 46, 63%), medullary thyroid (n = 19, 26%), and papillary thyroid (n = 6, 8%) cancers had 126 predominantly grade 1/2 (n = 124, 98%) MAEs, with 48% reporting greater than one MAE. Xerostomia (n = 49, 37%), rash (n = 24, 18%), periorbital edema (n = 16, 12%), and xerosis (n = 12, 9%) were the most common MAEs. The yearly cumulative incidence of all-grade MAEs was 55%, with a median time to onset of 57 (interquartile range: 15–166) days after initiation. Those with MAEs had a significantly higher percentage of lymphocytes (mean = 21.8, SD = 11.3, p = 0.005) compared with those without MAEs (16.9, SD = 10.0) and elevated immunoglobulin E (mean = 275, SD = 294.5 IU/mL). There were 18 (14%) MAE-related therapy interruptions, including the following: three (2%) rechallenged with dose maintained, 10 (7%) with a 50% dose reduction, 5 (4%) with a 25% dose reduction, and no drug discontinuations. A treatment algorithm was created for the most common MAEs: xerostomia managed with saliva and lubricants; mucositis with steroid rinses; rashes with topical steroids with or without topical ammonium lactate; periorbital edema with cold or caffeine compresses; and xerosis and pruritus with emollients. Conclusions: Selective RET inhibition is associated with a unique MAE profile. Early recognition and management of MAEs may improve quality of life, minimize interruptions, and maximize therapeutic benefit.http://www.sciencedirect.com/science/article/pii/S2666364325000086SelpercatinibMucocutaneous adverse eventRET fusionRET mutation |
| spellingShingle | Rachel E. Reingold, MD Rose Parisi, MD, MBA Guilherme Harada, MD Andrea P. Moy, MD George Dranitsaris, PhD Jasmine H. Francis, MD Julia Canestraro, OD, FAAO Julia A. Lester, MPH Lauren A. Kaplanis, RN Dazhi Liu, PharmD, BCOP Mario E. Lacouture, MD Alexander Drilon, MD Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292) JTO Clinical and Research Reports Selpercatinib Mucocutaneous adverse event RET fusion RET mutation |
| title | Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292) |
| title_full | Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292) |
| title_fullStr | Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292) |
| title_full_unstemmed | Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292) |
| title_short | Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292) |
| title_sort | mucocutaneous adverse events in patients with cancer treated with the highly selective ret kinase inhibitor selpercatinib loxo 292 |
| topic | Selpercatinib Mucocutaneous adverse event RET fusion RET mutation |
| url | http://www.sciencedirect.com/science/article/pii/S2666364325000086 |
| work_keys_str_mv | AT rachelereingoldmd mucocutaneousadverseeventsinpatientswithcancertreatedwiththehighlyselectiveretkinaseinhibitorselpercatinibloxo292 AT roseparisimdmba mucocutaneousadverseeventsinpatientswithcancertreatedwiththehighlyselectiveretkinaseinhibitorselpercatinibloxo292 AT guilhermeharadamd mucocutaneousadverseeventsinpatientswithcancertreatedwiththehighlyselectiveretkinaseinhibitorselpercatinibloxo292 AT andreapmoymd mucocutaneousadverseeventsinpatientswithcancertreatedwiththehighlyselectiveretkinaseinhibitorselpercatinibloxo292 AT georgedranitsarisphd mucocutaneousadverseeventsinpatientswithcancertreatedwiththehighlyselectiveretkinaseinhibitorselpercatinibloxo292 AT jasminehfrancismd mucocutaneousadverseeventsinpatientswithcancertreatedwiththehighlyselectiveretkinaseinhibitorselpercatinibloxo292 AT juliacanestraroodfaao mucocutaneousadverseeventsinpatientswithcancertreatedwiththehighlyselectiveretkinaseinhibitorselpercatinibloxo292 AT juliaalestermph mucocutaneousadverseeventsinpatientswithcancertreatedwiththehighlyselectiveretkinaseinhibitorselpercatinibloxo292 AT laurenakaplanisrn mucocutaneousadverseeventsinpatientswithcancertreatedwiththehighlyselectiveretkinaseinhibitorselpercatinibloxo292 AT dazhiliupharmdbcop mucocutaneousadverseeventsinpatientswithcancertreatedwiththehighlyselectiveretkinaseinhibitorselpercatinibloxo292 AT marioelacouturemd mucocutaneousadverseeventsinpatientswithcancertreatedwiththehighlyselectiveretkinaseinhibitorselpercatinibloxo292 AT alexanderdrilonmd mucocutaneousadverseeventsinpatientswithcancertreatedwiththehighlyselectiveretkinaseinhibitorselpercatinibloxo292 |